Advances in NKT cell Immunotherapy for Glioblastoma
Received Date: May 11, 2018 / Accepted Date: Jun 15, 2018 / Published Date: Jun 18, 2018
Type I or invariant natural killer T cells belong to a unique lineage of innate T cells, which express markers of both T lymphocytes and NK cells, namely T cell receptor (TCR) and NK1.1 (CD161C), respectively. Thus, apart from direct killing of target cells like NK cells, and they also produce a myriad of cytokines which modulate the adaptive immune responses. Unlike traditional T cells which carry a conventional ab TCR, NKT cells express semiinvariant TCR – Va14-Ja18, coupled with Vb8, Vb7 and Vb2 in mice. In humans, the invariant TCR is composed of Va24-Ja18, coupled with Vb11.
Keywords: NKT cell immunotherapy; Glioblastoma; T-cell receptor; T-lymphocyte; Cancer immunity; Brain tumor cells; Solid tumors
Citation: Pyaram K, Yadav V (2018) Advances in NKT cell Immunotherapy for Glioblastoma. J Cancer Sci Ther 10: 145-148. Doi: 10.4172/1948-5956.1000533
Copyright: © 2018 Pyaram K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
April 20-21, 2020 Berlin, Germany
- Total views: 2180
- [From(publication date): 0-2018 - Dec 09, 2019]
- Breakdown by view type
- HTML page views: 2100
- PDF downloads: 80